ACMG_CAP相关资料
################################
相关介绍
**********************************************

1.  2012年1月美国医学遗传学与基因组学学会（ACMG，American College of Medical Genetics and Genomics）委员会正式批准成立临床外显子和基因组测序工作小组，此小组的任务就是当病人进行外显子或基因组测序时发现的偶发突变给出推荐性的指导。2013年，ACMG发表了一篇关于临床的官方声明，明确强调了偶发变异可能对揭示患者病情、临床测试以及报告结果的重要性。

    `Rehm H L, Bale S J, Bayrak-Toydemir P, et al. ACMG clinical laboratory standards for next-generation sequencing[J]. Genetics in medicine, 2013, 15(9): 733-747. <https://www.nature.com/articles/gim201392>`_

    `Frampton G M, Fichtenholtz A, Otto G A, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing[J]. Nature biotechnology, 2013, 31(11): 1023-1031. <https://www.nature.com/articles/nbt.2696>`_

2.  2016年，ACMG更新了附带发现（secondary findings）的基因列表，他们推荐实验室在临床外显子和基因组测序结果中报告这些基因的突变。附带发现是指这些基因的变异与检测的初始目的没有关系，但会导致严重的疾病，目前关于这些变异的知识可以指导临床实践。ACMG发布这些建议的原因是，临床外显子组和基因组测序检测开始激增，但却缺乏相应的标准。ACMG不断更新的建议可以帮助确定哪些附带发现可以反馈给患者，对成年人和儿童患者都适用。最近更新后的列表包括81个基因。

    `Miller DT, et al. ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2023. <https://www.gimjournal.org/article/S1098-3600(23)00879-1/fulltext>`_

3.  早在2015年，美国医学遗传学和基因组学（ACMG）以及分子病理学协会（AMP）曾联合出版了变异位点解读指南，基于28个判断标准（criteria）将变异位点分为了Pathogenic、Likely pathogenic、Uncertain significance、Likely benign和Benign五个级别。同样，在2017年，AMP、ASCO和CAP也联合制定了体细胞突变变异位点解读指南，基于变异位点的临床意义将其分为Tier I、Tier II、Tier III、Tier IV四个级别。时隔两年，由中国遗传学会遗传咨询分会领衔的专家团队共同编译了《ACMG遗传变异分类标准与指南》中文版（以下简称“中文版”），并获得美国ACMG的官方授权。中文在线地址：http://acmg.cbgc.org.cn/doku.php?id=start

    `Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genetics in medicine, 2015, 17(5): 405-423. <https://www.nature.com/articles/gim201530>`_

    `Li M M, Datto M, Duncavage E J, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists[J]. The Journal of molecular diagnostics, 2017, 19(1): 4-23. <https://www.sciencedirect.com/science/article/pii/S1525157816302239>`_

4.  2019年ACMG又提供了关于拷贝数变异检测的临床指导意见，在分类上同样。

    `Mikhail F M, Biegel J A, Cooley L D, et al. Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC)[J]. Genetics in Medicine, 2019, 21(9): 1903-1916. <https://www.sciencedirect.com/science/article/pii/S1098360021050218>`_

其它相关文献
**********************************************

    `Ewing A D, Houlahan K E, Hu Y, et al. Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide-variant detection[J]. Nature methods, 2015, 12(7): 623-630. <https://www.nature.com/articles/nmeth.3407>`_

    `Santani A, Murrell J, Funke B, et al. Development and validation of targeted next-generation sequencing panels for detection of germline variants in inherited diseases[J]. Archives of Pathology and Laboratory Medicine, 2017, 141(6): 787-797. <https://meridian.allenpress.com/aplm/article/141/6/787/129007/Development-and-Validation-of-Targeted-Next>`_

    `Garcia E P, Minkovsky A, Jia Y, et al. Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer[J]. Archives of Pathology and Laboratory Medicine, 2017, 141(6): 751-758. <https://meridian.allenpress.com/aplm/article/141/6/751/129025/Validation-of-OncoPanel-A-Targeted-Next-Generation>`_

    `Jennings L J, Arcila M E, Corless C, et al. Guidelines for validation of next-generation sequencing–based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists[J]. The Journal of molecular diagnostics, 2017, 19(3): 341-365. <https://www.sciencedirect.com/science/article/pii/S1525157817300259>`_

    `张绪超, 梁智勇, 王升跃. 二代测序技术在肿瘤精准医学诊断中的应用专家共识[J]. 中华医学杂志, 2018, 98(26): 2057-2065. <https://rs.yiigle.com/CN112137201826/1049798.htm>`_

    `Roy S, Coldren C, Karunamurthy A, et al. Standards and guidelines for validating next-generation sequencing bioinformatics pipelines: a joint recommendation of the Association for Molecular Pathology and the College of American Pathologists[J]. The Journal of Molecular Diagnostics, 2018, 20(1): 4-27. <https://www.sciencedirect.com/science/article/pii/S1525157817303732>`_

    `Hume S, Nelson T N, Speevak M, et al. CCMG practice guideline: laboratory guidelines for next-generation sequencing[J]. Journal of medical genetics, 2019, 56(12): 792-800. <https://jmg.bmj.com/content/56/12/792.abstract>`_

    `Bean L, Funke B, Carlston C M, et al. Diagnostic gene sequencing panels: from design to report—a technical standard of the American College of Medical Genetics and Genomics (ACMG)[J]. Genetics in Medicine, 2020, 22(3): 453-461. <https://www.sciencedirect.com/science/article/pii/S1098360021012375>`_

    `CAP Accreditation Program-Molecular Pathology Checklist.pdf <reference/CAP Accreditation Program-Molecular Pathology Checklist.pdf>`_

    `Horak P, Griffith M, Danos A M, et al. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)[J]. Genetics in Medicine, 2022, 24(5): 986-998. <https://www.sciencedirect.com/science/article/pii/S1098360022000016>`_

FoundationOne 与MSK-IMPACT资料
**********************************************

    `FoundationOne CDx.pdf <https://info.foundationmedicine.com/hubfs/FMI%20Labels/FoundationOne_CDx_Label_Technical_Info.pdf>`_

    `FoundationOne CDxTM.pdf <reference/FoundationOne CDxTM.pdf>`_

    `De novo request for evaluation of automatic class III designation for the MSK-IMPACT.pdf <https://www.accessdata.fda.gov/cdrh_docs/reviews/den170058.pdf>`_

    *  MSK-IMPACT数据库:`<reference/http://www.cbioportal.org/study?id=msk_impact_2017>`_
    *  MSK-IMPACT数据分析Pipeline:`<reference/https://impact-pipeline.readthedocs.io/en/latest/index.html#>`_

    `Chalmers Z R, Connelly C F, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden[J]. Genome medicine, 2017, 9: 1-14. <https://link.springer.com/article/10.1186/s13073-017-0424-2>`_

    `Zehir A, Benayed R, Shah R H, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients[J]. Nature medicine, 2017, 23(6): 703-713. <https://www.nature.com/articles/nm.4333>`_

